Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Hypothermic Oxygenated Machine PErfusion During Ex-vivo SPLITting in Liver Pediatric Transplantation (HOPE SPLIT): A Multicenter Randomized Controlled Trial

NCT07918183 is registered in ClinicalTrials.gov with Hospices Civils de Lyon as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07918183 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
Hypothermic Oxygenated Machine PErfusion During Ex-vivo SPLITting in Liver Pediatric Transplantation (HOPE SPLIT): A Multicenter Randomized Controlled Trial
Lead sponsor
Hospices Civils de Lyon
Phase
Not applicable
Overall status
Not yet recruiting
Start date
January 31, 2027
Completion date
January 31, 2031
Enrollment
200 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

pediatric liver transplantation

Arms

As registered; 2 arms.

  • HOPE group ExperimentalEnd-ischemic Hypothermic Oxygenated Machine Perfusion (HOPE)

    Use of HOPE (End-ischemic Hypothermic Oxygenated Machine Perfusion) during ex vivo liver splitting

  • Classic static cold storage group Active comparatorClassic static cold storage

    Standard splitting technique performed during static cold storage

Primary endpoints

Registered primary outcome measures; 1 primary.

  • liver graft-related morbidity 1 year

    The primary endpoint is cumulative liver graft-related morbidity at 1 year after pediatric transplantation.

    The primary outcome measure will be the Comprehensive Complication Index which will be calculated as the total of all individual liver-related complications graded by the Clavien-Dindo score.

Lead sponsor's other trials

Hospices Civils de Lyon, most recent start first.